Massachusetts Institute of Technology

The General Hospital Corporation

Jonathan Braverman

Omer Yilmaz

Stephen J Lippard

George Eng

Fang Wang

Methods and compositions for enhancing Wnt signaling pathway activities in a tissue of a subject have been developed for the treatment of cancer, in particular cancers with one or more mutations in the APC (adenomatous polyposis coli) gene. Preferably, the amount of the compositions for enhancing Wnt signaling does not reduce or inhibit proliferation or viability of normal healthy cells in the subject. In some embodiments, pharmaceutical compositions including an effective amount of one or more GSK-3 inhibitors are administered to reduce cancer cell proliferation or viability in a subject. A preferred GSK-3 inhibitor is LY2090314 encapsulated within, or associated with nanoparticles. Dosage forms of LY2090314 encapsulated within, or associated with nanoparticles for administration are also described.

Compositions and methods for enhancing Wnt signaling for treating cancer

Platinum-containing compounds are generally described. For example, compounds of Formula (II) are generally described. Inventive compositions and uses thereof are also described. For example, methods of treating cancer in a subject comprising administering to the subject a therapeutically effective amount of a compound of Formula (II) are generally described. 

Growing community of inventors

Cambridge, MA, United States of America

Jonathan Braverman